NCT01313598View on ClinicalTrials.gov

GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions

Solid Tumors

Interventions

DRUG

GLPG0187

continuous IV infusion

Trial Locations (2)

1066 CX

Nationaal Kanker Instituut (NKI), Amsterdam

3584 CX

Universitair Medisch Centrum, Utrecht

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Galapagos NV

INDUSTRY

NCT01313598 - GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter